tiprankstipranks
Advertisement
Advertisement
Benitec Biopharma announces interim Phase 1b/2a study of BB-301
PremiumThe FlyBenitec Biopharma announces interim Phase 1b/2a study of BB-301
3M ago
Benitec Biopharma: Emerging BB-301 Clinical Profile and Upcoming Data Catalyst Support Buy Rating and $32 Target
Premium
Ratings
Benitec Biopharma: Emerging BB-301 Clinical Profile and Upcoming Data Catalyst Support Buy Rating and $32 Target
3M ago
Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year
Premium
The Fly
Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year
4M ago
Benitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating
PremiumRatingsBenitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating
7M ago
Citizens JMP healthcare analysts hold an analyst/industry conference
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference
7M ago
Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses
Premium
Company Announcements
Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses
7M ago
Positive Buy Rating for BB-301 Driven by Promising Trial Results and Potential Market Acceleration
PremiumRatingsPositive Buy Rating for BB-301 Driven by Promising Trial Results and Potential Market Acceleration
7M ago
Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright
Premium
The Fly
Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright
7M ago
Benitec Biopharma price target raised to $22 from $20 at Citizens JMP
Premium
The Fly
Benitec Biopharma price target raised to $22 from $20 at Citizens JMP
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100